Get the Stockscreener App
2.2452
7.60%
-0.1848
Cns Pharmaceuticals Inc stock is traded at $2.2452, with a volume of 157.26K.
It is down -7.60% in the last 24 hours and down -53.32% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$2.43
Open:
$2.36
24h Volume:
157.26K
Relative Volume:
0.29
Market Cap:
$3.36M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.0317
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-22.04%
1M Performance:
-53.32%
6M Performance:
-70.26%
1Y Performance:
-99.71%
1-Day Range:
$2.20
$2.36
1-Week Range:
$2.20
$2.90
52-Week Range:
$2.20
$1,195.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
2.24 | 3.36M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.16 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.70 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNSP stock touches 52-week low at $2.2 amid sharp annual decline By Investing.com - Investing.com South Africa
CNS Pharmaceuticals jumps on current cash position update - MSN
CNS Pharmaceuticals secures NASDAQ listing and funding into 2026 By Investing.com - Investing.com South Africa
CNS Pharmaceuticals reports cash position of $14M as of February 26 - TipRanks
CNS Pharmaceuticals secures NASDAQ listing and funding into 2026 - Investing.com
Can CNS Pharmaceuticals' $14M War Chest Deliver on Its Promising Brain Cancer Treatment? - StockTitan
CNS Pharmaceuticals to implement 1-for-50 reverse stock split - MSN
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference - The Globe and Mail
CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN
CNSPCNS Pharmaceuticals Latest Stock News & Market Updates - StockTitan
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum - ACCESS Newswire
CNS Pharmaceuticals enacts 1-for-50 reverse stock split - Investing.com
CNSP stock touches 52-week low at $0.08 amid sharp annual decline - Investing.com India
CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down -February 19, 2025 at 10:28 am EST - Marketscreener.com
Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - StockTitan
Can This Drastic 1:50 Reverse Split Save CNS Pharmaceuticals' Nasdaq Listing? - StockTitan
CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit - TipRanks
Revolutionary Brain Barrier-Crossing Cancer Drug Takes Center Stage at GBM Summit - StockTitan
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit - Yahoo Finance
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) - ACCESS Newswire
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
CNSP’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Does Cns Pharmaceuticals Inc (CNSP) offer a good opportunity for investors? - SETE News
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference - ACCESS Newswire
CNS Pharma's Breakthrough Brain Cancer Pipeline Takes Center Stage at Elite BIO CEO Conference - StockTitan
Key Market Driver in Generic Central Nervous System Drugs Industry 2025: Rising Incidence Of Mental Health ... - WhaTech
Ladenburg Thalmann slashes price target on Cns Pharmaceuticals Inc [CNSP] – find out why. - The DBT News
Cns Pharmaceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
CNSP’s price-to-book ratio: An indicator of the company’s performance - US Post News
Boston biotech Atalanta raises $97M to bring CNS drugs into clinic - The Business Journals
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - ACCESS Newswire
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference - ACCESS Newswire
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment - ACCESS Newswire
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity - ACCESS Newswire
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference - ACCESS Newswire
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - ACCESS Newswire
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - ACCESS Newswire
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date - ACCESS Newswire
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) - ACCESS Newswire
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering - ACCESS Newswire
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - ACCESS Newswire
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results - ACCESS Newswire
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - ACCESS Newswire
CNS Pharmaceuticals Announces Reverse Stock Split - ACCESS Newswire
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea - Business Wire
Central Nervous System (CNS) Therapeutics Market Forecast - GlobeNewswire
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):